GMDA | Gamida Cell Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0320 - 0.0395
52 Week Range	0.0300 - 2.5100
Beta	1.00
Implied Volatility	620.79%
IV Rank	100.00%
Day's Volume	19,048,523
Average Volume	9,377,545
Shares Outstanding	132,639,000
Market Cap	4,337,295
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-10-26

Valuation
Profitability
Growth
Health
P/E Ratio	-0.04
Forward P/E Ratio	N/A
EPS	-0.82
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	143
Country	Israel
Website	GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

GMDA's peers: BCLI, CANF, ENLV, EVGN, ORMP, PLX

*Chart delayed

Analyzing fundamentals for GMDA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see GMDA Fundamentals page.

Watching at GMDA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GMDA Technicals page.